ATE338552T1 - Verwendungen von et743 zur behandlung von krebs - Google Patents

Verwendungen von et743 zur behandlung von krebs

Info

Publication number
ATE338552T1
ATE338552T1 AT00927584T AT00927584T ATE338552T1 AT E338552 T1 ATE338552 T1 AT E338552T1 AT 00927584 T AT00927584 T AT 00927584T AT 00927584 T AT00927584 T AT 00927584T AT E338552 T1 ATE338552 T1 AT E338552T1
Authority
AT
Austria
Prior art keywords
treat cancer
cancer
treat
Prior art date
Application number
AT00927584T
Other languages
German (de)
English (en)
Inventor
Angela Bowman
Esteban Cvitkovic
George Demetri
Cecilia Guzman
Jose Jimeno
Lazaro Luis Lopez
Jean Louis Misset
V Couturier Paul
C Twelves
Hoff Daniel D Von
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of ATE338552T1 publication Critical patent/ATE338552T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT00927584T 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs ATE338552T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound

Publications (1)

Publication Number Publication Date
ATE338552T1 true ATE338552T1 (de) 2006-09-15

Family

ID=27546594

Family Applications (3)

Application Number Title Priority Date Filing Date
AT00927584T ATE338552T1 (de) 1999-05-13 2000-05-15 Verwendungen von et743 zur behandlung von krebs
AT06011784T ATE375795T1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
AT06014005T ATE500830T1 (de) 1999-05-13 2000-05-15 Behandlung von krebs beim menschen mit et743

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT06011784T ATE375795T1 (de) 1999-05-13 2000-05-15 Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
AT06014005T ATE500830T1 (de) 1999-05-13 2000-05-15 Behandlung von krebs beim menschen mit et743

Country Status (32)

Country Link
US (1) US8119638B2 (cg-RX-API-DMAC7.html)
EP (3) EP1702618B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002544231A (cg-RX-API-DMAC7.html)
KR (1) KR20020019914A (cg-RX-API-DMAC7.html)
CN (2) CN1360503A (cg-RX-API-DMAC7.html)
AR (1) AR028476A1 (cg-RX-API-DMAC7.html)
AT (3) ATE338552T1 (cg-RX-API-DMAC7.html)
AU (2) AU777417B2 (cg-RX-API-DMAC7.html)
BG (1) BG65680B1 (cg-RX-API-DMAC7.html)
BR (1) BR0010531A (cg-RX-API-DMAC7.html)
CA (1) CA2373794C (cg-RX-API-DMAC7.html)
CY (4) CY1105818T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ301482B6 (cg-RX-API-DMAC7.html)
DE (4) DE122008000013I1 (cg-RX-API-DMAC7.html)
DK (3) DK1176964T3 (cg-RX-API-DMAC7.html)
ES (2) ES2272279T3 (cg-RX-API-DMAC7.html)
FR (1) FR08C0013I2 (cg-RX-API-DMAC7.html)
HU (2) HU229866B1 (cg-RX-API-DMAC7.html)
IL (2) IL146434A0 (cg-RX-API-DMAC7.html)
LU (1) LU91418I2 (cg-RX-API-DMAC7.html)
MX (1) MXPA01011562A (cg-RX-API-DMAC7.html)
MY (1) MY164077A (cg-RX-API-DMAC7.html)
NL (1) NL300337I2 (cg-RX-API-DMAC7.html)
NO (2) NO324564B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ515423A (cg-RX-API-DMAC7.html)
PL (1) PL198185B1 (cg-RX-API-DMAC7.html)
PT (3) PT1176964E (cg-RX-API-DMAC7.html)
SI (3) SI1716853T1 (cg-RX-API-DMAC7.html)
SK (1) SK287580B6 (cg-RX-API-DMAC7.html)
TR (1) TR200103819T2 (cg-RX-API-DMAC7.html)
UA (1) UA74782C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000069441A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
IL155781A0 (en) * 2000-11-06 2003-12-23 Pharma Mar Sa Effective antitumor treatments
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
US20050004018A1 (en) * 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
US7622458B2 (en) * 2003-11-13 2009-11-24 Pharma Mar, S.A.U. Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
NZ552607A (en) * 2004-07-09 2009-07-31 Pharma Mar Sa Prognostic molecular markers
DE602005014380D1 (de) * 2004-10-26 2009-06-18 Ortho Biotech Products L P Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
DE602005001833T2 (de) * 2004-10-29 2008-04-17 Pharma Mar S.A., Sociedad Unipersonal Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
EP2023931A2 (en) * 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EP3412293A4 (en) * 2016-02-04 2019-10-16 Jiangsu Hengrui Medicine Co., Ltd. INJECTABLE PHARMACEUTICAL COMPOSITION WITH TRABECTEDIN FOR EXTERNAL GASTROINTESTINAL USE AND METHOD FOR THE PRODUCTION THEREOF
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
KR20230002462A (ko) 2020-04-15 2023-01-05 에버 발린젝트 게엠베하 트라벡테딘 및 아미노산을 포함하는 조성물
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
US12303506B2 (en) 2022-01-20 2025-05-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3774435D1 (de) * 1986-06-09 1991-12-12 Univ Pennsylvania Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
PT1586322E (pt) * 1996-11-05 2008-10-27 Childrens Medical Center Composições que compreendem talidomida e dexametasona para o tratamento de cancro
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
PL196809B1 (pl) * 1998-04-06 2008-02-29 Univ Illinois Półsyntetyczne ekteinascydyny, kompozycje farmaceutyczne oraz zastosowanie półsyntetycznych ekteinascydyn
HUP0101960A3 (en) * 1998-05-11 2003-03-28 Pharma Mar Sa Metabolites of ecteinascidin 743, their use and pharmaceutical compositions containing them
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
DE60111845T2 (de) 2000-04-12 2006-04-27 Pharma Mar, S.A., Tres Cantos Ecteinaschidin derivate mit antikrebs wirkung
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
WO2002014554A2 (en) 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
IL155781A0 (en) 2000-11-06 2003-12-23 Pharma Mar Sa Effective antitumor treatments
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
US20030027799A1 (en) 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20050004018A1 (en) 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
US7622458B2 (en) 2003-11-13 2009-11-24 Pharma Mar, S.A.U. Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
NZ552607A (en) 2004-07-09 2009-07-31 Pharma Mar Sa Prognostic molecular markers
CN101068596A (zh) 2004-09-29 2007-11-07 法马马私人股份有限公司 艾可特耐思地作抗炎药
DE602005014380D1 (de) 2004-10-26 2009-06-18 Ortho Biotech Products L P Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
DE602005001833T2 (de) 2004-10-29 2008-04-17 Pharma Mar S.A., Sociedad Unipersonal Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
ES2361566T3 (es) 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
EP2023931A2 (en) 2006-05-12 2009-02-18 Pharma Mar S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
BR0010531A (pt) 2002-06-04
DE60036826D1 (de) 2007-11-29
NO20015516D0 (no) 2001-11-12
DK1176964T3 (da) 2007-01-15
IL146434A0 (en) 2002-07-25
AU777417B2 (en) 2004-10-14
SI1702618T1 (sl) 2008-02-29
CZ20014081A3 (cs) 2002-11-13
MY164077A (en) 2017-11-30
LU91418I2 (fr) 2008-05-13
CN1679631A (zh) 2005-10-12
HUP0201187A3 (en) 2002-11-28
PL352931A1 (en) 2003-09-22
HU229866B1 (en) 2014-10-28
DE60036826T2 (de) 2008-08-28
EP1716853B9 (en) 2011-09-28
FR08C0013I1 (cg-RX-API-DMAC7.html) 2008-05-30
SI1716853T1 (sl) 2011-10-28
CY2008007I2 (el) 2009-11-04
DK1702618T3 (da) 2008-02-25
CY2008007I1 (el) 2009-11-04
NL300337I1 (nl) 2008-05-01
NO20015516L (no) 2002-01-11
ES2294756T3 (es) 2008-04-01
NZ515423A (en) 2004-04-30
EP1716853A2 (en) 2006-11-02
EP1702618A3 (en) 2006-12-27
FR08C0013I2 (fr) 2009-10-30
HUS1500001I1 (hu) 2016-08-29
DE60045720D1 (de) 2011-04-21
AU2005200180B2 (en) 2007-12-13
TR200103819T2 (tr) 2002-04-22
AU4597500A (en) 2000-12-05
EP1176964B8 (en) 2007-10-10
BG106171A (en) 2002-06-28
PL198185B1 (pl) 2008-06-30
CY1105818T1 (el) 2011-02-02
DE60030554T2 (de) 2007-09-13
KR20020019914A (ko) 2002-03-13
HUP0201187A2 (en) 2002-09-28
CN100477993C (zh) 2009-04-15
EP1176964B1 (en) 2006-09-06
AR028476A1 (es) 2003-05-14
ATE500830T1 (de) 2011-03-15
NO2008005I2 (cg-RX-API-DMAC7.html) 2010-09-27
EP1716853B1 (en) 2011-03-09
DE122008000013I1 (de) 2008-08-07
CN1360503A (zh) 2002-07-24
IL146434A (en) 2008-03-20
UA74782C2 (uk) 2006-02-15
NO324564B1 (no) 2007-11-19
US8119638B2 (en) 2012-02-21
CY1112753T1 (el) 2016-02-10
EP1702618A2 (en) 2006-09-20
NO2008005I1 (no) 2008-06-09
SK287580B6 (sk) 2011-03-04
SI1176964T1 (sl) 2007-02-28
SK16442001A3 (sk) 2002-03-05
WO2000069441A1 (en) 2000-11-23
LU91418I9 (cg-RX-API-DMAC7.html) 2019-01-02
EP1176964A1 (en) 2002-02-06
CZ301482B6 (cs) 2010-03-17
CA2373794A1 (en) 2000-11-23
JP5777562B2 (ja) 2015-09-09
DK1716853T3 (da) 2011-06-27
AU2005200180B9 (en) 2008-05-29
ES2272279T3 (es) 2007-05-01
NL300337I2 (nl) 2008-09-01
CA2373794C (en) 2005-10-11
EP1702618B1 (en) 2007-10-17
PT1716853E (pt) 2011-05-12
JP2002544231A (ja) 2002-12-24
BG65680B1 (bg) 2009-06-30
PT1176964E (pt) 2007-01-31
DE60030554T8 (de) 2008-01-10
CY1107143T1 (el) 2010-07-28
MXPA01011562A (es) 2002-07-30
EP1716853A3 (en) 2006-11-15
ATE375795T1 (de) 2007-11-15
US20070275942A1 (en) 2007-11-29
JP2012149095A (ja) 2012-08-09
PT1702618E (pt) 2008-01-11
AU2005200180A1 (en) 2005-02-10
DE60030554D1 (de) 2006-10-19

Similar Documents

Publication Publication Date Title
ATE338552T1 (de) Verwendungen von et743 zur behandlung von krebs
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
DE60103137D1 (de) Impstoff zur behandlung von atherosclerosis
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
ATE254913T1 (de) Diacerein zur behandlung von psoriasis
EP1117431A4 (en) TREATMENT OF ACIDOSIS
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
EP1315503A4 (en) TREATMENT AGAINST URINARY DYSFUNCTION
DE60103685D1 (de) Behandlung von Poriomania
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE60103503D1 (de) Verwendung von fsh zur behandlung von infertilität

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1176964

Country of ref document: EP